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SUMMARY 
The present prospective study is conducted to determine the prophylactic value of antiparkin-
sonian drug (A. P.) at the time of initiation of antipsychotic therapy. Seventy patients were selected who 
fulfilled the selection criteria. Thirty five patients received antipsychotic drugs alone (Group A), while 
another thirty five patients received A. P. drugs concurrently with antipsychotic drugs (Group B.) These 
patients were assessed weekly for 4 weeks for ?.ny extra pyramidal symptoms (E. P. S.
1) There was no 
statistically significant difference between E. P. S. scores of the two groups in different weeks. The diffe-
rence in percentage of patients who developed E. P. S. in different weeks in bcth the groups was statis-
tically no'i-slgnificant (p<0.0fi). None of the female subjects developed E. P. S. in either group. 
Phenothiazines and other neurolep-
tics which are commonly used in psychia-
try, are known to cause extrapyramidal 
symptoms (E. P. S.). The incidence of 
E. P. S. is 38.9% in patients treated with 
phenothiazines (Ayd, 1961; Laverne, 
1961). Ayd (1961) reported 35% E. P.S. 
with chlorpromazine, 43% with prochlor-
promazine, 44% with thioproperazate, 
36% with perphenazine, 60% with trifluo-
perazine and 52% with fluphenazine. 
Parkinsonism like syndrome following 
antipsychotic medication can be patient 
related or dose related (Danial & Freed-
man, 1973). 
Ayd (1961) has reported that 90% 
dyskinesias appear within first 4$ days 
and time and dosage are less important 
than individual susceptibility. Now-a-
days, a high percentage of psychiatric 
patients treated by antipsychotic drugs 
receive concurrently one or the other 
antiparkinsonian (A. P.) medication, 
though antiparkinsonian medication has 
known toxic properties. Furthermore it 
has not been established that widespread 
use of A. P. medication as a preventive 
measure is necessary or desirable. It is 
a hypothesis that such use of these drugs 
isoccasionaly required. Klett and Caffey 
(1972) andDismascio & Demirgian (1970) 
concluded that the hazards of polyphar-
macy outweigh the advantage of prophy-
laxis and that A. P. drugs are overused. 
It is also significant that some patients 
treated with phenothiazines do not seem to 
develop E. P. S., although they benefit 
by the antipsychotic properties of the 
phenothiazines (Davis & Casper, 1978). 
A. P. prophylaxis as a routine, for all 
patients, given with neuroleptic drugs 
doesn't always prevent E. P. S. and may 
even increase the frequency of rigidity and 
akathisia in some patients (Dismascio and 
Demirgian, 1970; Coleman and Hayes, 
1975). 
Previous researches conducted were in 
the area of evaluating long term need for 
A. P. drugs for chronic Schizophrenics 
(Orlov et al., 1971; Klett & Caffey, 1972; 
McClelland, 1974, Rifkin, 1978). It has 
been reported that discontinuance of A.P. 
drugs did not increase the rate of E. P. S. 
among receipients of antipyschotic drugs 
(Dismascio and Demirgian, 1970). 
LIMITATIONS OF PREVIOUS RESEARCHES: 
The limitations are that Klett (1972), 
Mc Clelland (1974), Rifkin (1978), Orlov et 
al. (1971) have studied those patients who 
were already on phenothiazines and A. P. 
medication for more than 3 to 6 months 
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and in sonic studies even 4 to 5 years; 
were selected and in few patients A. P. 
drugs withdrawal were with placebo sub-
stitution. None of the authors indeed 
studied prophylactic role of A. P. drugs at 
the initiation of antipsychotic therapy, be-
cause if A. P. drugs are given in conjunc-
tion with phenothiazines for more than 
3-6 month the requirement of A. P. drugs 
are practically nil. Mc Clelland (1974) 
reported that great majority of patients 
who have been on A. P. drugs for over 3 
months these drugs are unnecessary and 
can be withdrawn without disadvantage. 
The A. P. medications if administered 
in conjunction with antipsychotic drugs, 
have following disadvantages: 1. Many 
patients never manifest E. P. S. (Davis and 
Gasper, 1978). 2. There are side effects 
associated with high doses of antiparkinso-
nian medication including dry mouth, 
blurred vision and very rarely paralytic 
ileus and urinary retention. 3. The ex-
pense of treatment is increased. 4. There 
is no absolutely convincing evidence that 
prophylactic routine use of A. P. medica-
tion prevents the occurence of E. P. S. 
Goodman and Gilman( 19 75) reported that 
A. P. medication is valid only for their 
rapid control and not to prevent their po-
ssible occurence or to mask their actual 
occurence. 5. Patients can, rarely de-
velop behavioural toxicity and toxic psy-
chosis (Kazamatsuri et al., 1972; Johnson, 
1972; Gerlach^a/., 1974; Marsden, 1975) 
6. The chief neurological side effect i. e. 
parkinsonism is often (but not always) to 
some degree a necessary accompaniment of 
therapeutic benefit in the treatment of 
psychosis (Goldman, 1958). Positive rela-
tions between E. P. S. and therapeutic 
effects also were reported (Freyhan, 1957; 
Denham, 1961; Brunn, 1962). 7. A. P. 
medication added to phenothiazines lower 
the plasma levels of chlorpromazine (Chan 
el al., 1973; Loga et al., 1975; Rivera— 
Calimlim et al., 1976) and possibly reduce 
the therapeutic effects (Ayd, 1961; Singh 
and Smith, 1973). A. P. drugs have also 
been reported to influence the absorption 
of drugs from the gut (Rivera Calimlim, 
1976). Recently it has been proved to 
be a controversial issue (Simpson et al., 
1980). 8. Poor drug compliance many 
patients only continue A. P. medicine and 
stop antipsychotic drugs in follow up, as 
A. P. medicines are cheaper than antipsy-
chotic drugs (Behere and Ramakrishna, 
1980). 
AIM 
The present study was conducted to 
determine whether there is any prophylac-
tic role of A. P. drugs at the time of initia-
tion of antipsychotic therapy. 
METHODS 
Seventy patients were selected from 
Psychiatry Department of Institute of 
Medical Sciences, B. H. U., Varanasi. 
Following were the selection criteria. 
SELFCTION CRITERIA 
1. Only newly registered cases were in-
cluded in study from May 79 on-wards. 
2. Only those patien ts coming from Vara-
nasi city proper and neighbouring 
villages of Varanasi District were 
included in the study so as to ensure 
weekly regular follow up. 
3. The age range was between 15 to 45 
years. 
4. The clinical diagnosis was that of 
functional psychosis. 
5. Only those patients who were not on 
any antipsychotic drugs or any A. P. 
drugs at the time of inclusion in the 
study. 
6. There should be no evidence of brain 
damage or neurological disorder such 
as primary parkinsonism. 
7. Patients who were on thioridazine 
alone were excluded, as this 
drug has extremely low incidence 
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DESIGN 
A total of seventy patients who fulfil-
led the above criteria were included in 
the study, they were divided into two com-
parison groups of 35 each. Group A 
which consisted of 35 patients was 
given only antipsychotic drugs. The 
medication was adjusted according to the 
needs of the individual patients. Combi-
nation of antipsychotic drugs was avoided 
as far as possible. Group B consisted of 
35 patients who were given A. P. drugs 
(Trihexyphenidyl Hcl) at the time of 
initiating antipsychotic therapy. In this 
group too, dose of antipsychotic drug was 
adjusted according to the needs of the 
individual patients. The trial was blind 
in that the clinical assessors were unaware 
which patients had received A. P. for pro-
phylaxis at the initiation of antipsychotic 
medications. 
Patients were assessed for any E.P.S. 
weekly on semistructured proforma (can 
be had from authors on request) which 
included various sub-items viz. tremors, 
autonomic symptoms (sialorrhoea etc.) 
general symptoms (gait, facies, posture, 
speech, swallowing difficulty, lost arm 
swing), rigidity, akathisia dys tonic 
reaction, dyskinesias. For training pur-
poses assessors had assessed few patients 
before start of trial, and after discussion, 
reached a consensus. 
All the patients were assessed before 
the start of the study for any E.P..S. 
Patients of both groups were weekly 
assessed for individual symptoms for 4 
weeks. If any patient in Group A deve-
loped E. P. S. of such severity that A. P. 
medication had to be started were given 
A. P. drugs but then for subsequent weeks 
he was not included for further assessment. 
RESULTS 
Table 1 shows the age distribution of 
both groups. The mean age in Group A 
was 21.91 years and 24.82 years in Group 
B. There was no statistically significant 
TABLE 1. Age Distribution 
Years Groups 
A B 
15—19 
20—24 
25—29 
30—34 
35—39 
40—44 
Mean 
S.D. 
N 
13 
12 
6 
2 
1 
1 
% 
37.1 
34.3 
17.1 
5.7 
2.9 
2.9 
21.91 
5.85 
N 
15 
6 
3 
3 
4 
4 
% 
42.9 
17.1 
8.6 
8.6 
11.4 
11.4 
24.82 
8.48 
difference between the two groups (t= 1.79, 
d.f.=68, N. S.). 24(68.6%) patients were 
male and 11 (31.4%) were female in Group 
A, while in group B male to female ratio 
was 8to 7 respectively. Patients included in 
study were 8(22.8%) from O. P. D. and 
27(77.1%) from indoor in group A; while 
in group B distribution was 15(42.8%) 
and 20(57.1%) respectively, Disease 
wise break up was 32 (91.4%) schizophre-
nics and 3(8.67%) MDP (Mania), in both 
the groups. The mean daily chlorproma-
zine equivalent dose of 35 patients who 
received antipsychotic alone was 711.52 
mg; while of 35 patients who also 
received A. P. drug prophylaxis was 
951.42 mg. 
In group A all 35 patients were 
assessed in the first week, 21 patients were 
assessed in second week (because 14 
patients developed E.P.S. of such severity 
that patients had to be switched on to 
A.P. medication, and then not included for 
subsequent weeks), similarly 15 patients 
were assessed in third week (6 more pa-
tients were switched on to A.P. drugs). 15 
patients were assessed in the fourth week. 
All 35 patients were asessed for four weeks 
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TABLE 2. Number of patients assessed in 
different weeks 
Weeks 
I 
II 
III 
IV 
35 (100) 35 (100) 
21* (60) 35 (100) 
15** (42.85) 35 (100) 
15 (42.85) 35 (100) 
*14 patients developed severe E. P. S. for which 
A. P. drugs were added and discontinued from 
study from 2nd week onwards. 
* *6 more patients developed EPS and put on A.P. 
drugs and discontinued from study from 3rd 
week onwards. 
outs in both group, all were available for 
follow up. 
Total scores of E. P. S. in both the 
groups in different weeks are shown in 
table 3. There is no statistically signifi-
cant difference between the E. P. S. scores 
in both groups in different weeks. 
TABLE 3. Total scores of E.P. S. in both 
Groups 
Groups 
Weeks 
I 
II 
III 
IV 
No. 
of 
Pts 
35 
21 
15 
15 
A 
Scores 
65 
13 
6 
3 
No. 
of 
Pts. 
35 
35 
35 
35 
B 
Scores 
31 
33 
40 
26 
t d. f. 
1.32 68 
0.625 54 
0.98 48 
0.89 48 
All t values arc not significant 
Percentage of patients who developed 
E. P. S. in both the groups in different 
weeks are shown in table-4. 
After applying analysis of variance 
the difference between two groups are sta-
tistically nonsignificant (p>0.05). These 
are neither dependent on weeks nor on 
drugs. 
TABLE 4. Percentage of patients, developed 
E.P.S. in both groups 
Group A (%) Group B (%) Weeks 
I 
II 
III 
IV 
A 
31.42 
23.80 
26.66 
20.00 
B 
22.85 
22.85 
25.71 
17.14 
Analysis of Variance—p.<0.05 
The rates of E. P. S. among antipsy-
chotic recipients according to receipt and 
nonreceipt of A. P. medication prophylaxis 
at the end of four weeks are shown in 
table-5. 14.3% patients developed E.P.S. 
TABLE 5. Rates of E. P. S. among anti-
psychotic recipients according to 
receipt and nonreceipt of A. P. 
drug prophylaxis at the end of 
4 weeks 
No. (%) 
E.P.S. 
Total 
with 
No (A) 
3(20) 
15 
Yes (B) 
6 (17.14) 
35 
Total 
9 (18) 
56 
among patients below 25 yrs. of age and 
25% developed among above 25 yrs. of age 
in group A, while it was 19% and 14.3% 
in group B respectively. E. P. S. was 
commonly seen in male subjects in both 
groups, while none of the female patients 
developed E.P.S. in either group. How-
ever, the rates for those who did not and 
those who did receive A. P. drug as pro-
phylaxis were 30% and 21.4% respective-
ly (table-6). Patients were categorized; 
according to the presence of tremors auto-
nomic symptoms, akathisia, and dystonic 
reactions (General symptoms). Among 
35 patients in group A tremors were obser-
ved in 10 (28.69%), autonomic symptoms 
in 3 (8.6%), akathisia in 2 (5.7%), dysto-210  P. B. BEHERE, AND P. RAMAKRISHNA 
TABLE 6. Rales of E. P. S. among anti-
psychotic recipients according to 
receipt or non receipt of A. P. 
drug as prophylaxis according to 
age and sex at the end of 4 
weeks 
A. P. Medication Prophylaxis 
No Yes 
No. of No. with EPS No. of No. with 
PTS PTS E. P. S. 
Age (in yr.) 
25 7 1(14.3%) 
25 8 ?(25.0%) 
Sex 
M 10 3(30.0%) 
F 5 0 
21 4(19.0%) 
14 2(14.3%) 
28 6(21.4%) 
7 0 
nic reactions in 5(14.3%) and general 
symptoms in 5 (14.3%). The correspon-
ding frequancies in 35 patients of Group B 
were 10 (28.6%), 1 (2.8%), 1 (2.8%), 2 
(5.7%), none developed dystonic reaction, 
7 (20%). 
DISCUSSION 
The treatment of E. P. S. is a subject 
of dispute, some psychiatrists advocating 
the use of prophylactic A. P. medication 
while others reserve such drugs for the 
treatment of emergenty symptoms. Cent-
rally acting anticholinergic-antiparkinso-
nian drugs successfully relieve emergent 
E. P. S. but A. P. prophylaxis as a routine 
for all patients, given neuroleptic drugs, 
doesn't always prevent E. P. S. 
From this study it is evident that A. P. 
medication (Trihexyphenidyl Hcl) has no 
prophylactic value in occurrence of E.P.S. 
age and sex, as well as many other factors, 
were evaluated to determine whether they 
could have obscured the prophylactic 
effect due to A. P. medication. None of 
these factors materially affected the re-
sults. 
E. P. S. commonly seen in males in 
both the groups while none of the female 
patients developed E. P. S. in the two 
groups. This is in conformity with that of 
Chester et al. (1977). The dystonic re-
action which was seen only in Group A 
(14.3%) and not in group B is an impor-
tant observation. It is also possible that 
certain types of E. P. S. may be pre-
vented by A. P. drugs (Trihexyphenidyl 
Hcl), while others are not. The authors 
suggest that there is no prophylactic use 
of A. P. medication concurrently with 
initiation of antipsychotic therapy. 
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